Cardiomyopathy in Pompe disease

Article written and reviewed by Dr Luca Moretti

Pompe disease, or glycogen storage disease type II, is an autosomal recessive disorder caused by biallelic GAA variants and deficiency of lysosomal acid alpha-glucosidase. Glycogen reaching the lysosome is not degraded, distends the compartment and interferes with autophagy and the contractile apparatus. In classic infantile disease, the heart rapidly accumulates material and develops biventricular hypertrophic cardiomyopathy; in late-onset disease, weakness of axial and respiratory muscles predominates. The amount of residual activity contributes to this major difference without being the only modifier.

Before enzyme replacement therapy, classic infantile disease generally led to cardiorespiratory death within the first year. Recombinant enzyme has radically changed survival and can reduce cardiac mass within months, but it does not equalize outcomes: age at treatment initiation, CRIM status, antibodies, genotype, nutrition and neuromuscular damage continue to matter. Treated disease therefore has a new natural history, with chronic needs not anticipated by the old paradigm.

Classic infantile and late-onset forms

In the first months, the classic infant presents with hypotonia, weakness, poor head control, macroglossia, sucking difficulty, failure to thrive, respiratory infections and cardiomegaly. Tachypnea may simultaneously reflect heart failure, diaphragmatic weakness and aspiration. Hepatomegaly often results from congestion or storage without the severe hepatic dysfunction of hepatic glycogenoses. The cardiorespiratory syndrome should trigger urgent GAA testing.

Late-onset forms may appear from childhood to adulthood with proximal, axial and diaphragmatic weakness, lordosis, scapular winging and nocturnal dyspnea. Respiratory impairment may be disproportionate to limb weakness and precede a severely reduced seated spirometry. Major hypertrophic cardiomyopathy is unusual; when present, variant, age and alternative diagnoses should be checked. Phenotypic separation avoids denying Pompe disease because the heart is normal or attributing common hypertension to it.

Some infants have GAA deficiency and early symptoms without classic cardiomyopathy, classified along the nonclassic or late-onset continuum. Newborn screening further expands the spectrum by identifying presymptomatic children, late-onset variants and pseudodeficiency alleles. Label and therapy cannot derive from the screening test alone. Post-screening confirmation integrates activity in a second sample, genetics, Glc4 and organ assessment.

Cardiac and electrocardiographic phenotype

Echocardiography shows concentric thickening of the left ventricle and often of the right ventricle, increased mass, a small cavity and possible obstruction. Ejection fraction may be hyperdynamic initially, but relaxation is impaired and function declines without treatment. The dynamic gradient makes dehydration and abrupt preload reduction dangerous. Lysosomal pseudohypertrophy should not be managed as sarcomeric HCM without considering the entire infantile phenotype.

The typical ECG combines a short PR, very high and broad QRS complexes, hypertrophy criteria and repolarization abnormalities. The short PR reflects accelerated conduction through glycogen-rich tissue and does not always indicate an accessory pathway. Supraventricular tachycardia, pre-excitation and ventricular arrhythmias may occur, and risk increases during anesthesia or critical illness. Electrical surveillance continues even as wall thickness regresses because the conduction system and myocardium do not recover at the same rate.

The reduction in mass after therapy is often striking but is not synonymous with systemic cure. Strain, diastolic function, rhythm and functional capacity must be followed together. In late-onset disease, a baseline ECG and echocardiogram are appropriate; subsequent monitoring depends on findings, symptoms and protocols, while respiratory management remains the priority. Subtype-based phenotyping avoids an identical testing burden for biologically different diseases.

Enzymatic and genetic diagnosis

GAA activity can be measured in dried blood spot, leukocytes, fibroblasts or muscle using validated methods. Dried blood is rapid and suitable for screening, but low values must be confirmed because sample quality, pseudodeficiency and interference produce false positives. In infantile disease, urgency requires confirmation and therapeutic preparation to proceed in parallel. Speed with rigor is preferable both to sequential waiting and to treatment based on a single doubtful test.

Definitive diagnosis identifies two pathogenic or likely pathogenic variants in trans, concordant with enzyme deficiency. Deletions, duplications or deep variants may require additional techniques. The common intronic c.-32-13T>G variant is often associated with late-onset disease in certain populations, but the second allele and phenotype modify onset. An isolated VUS is not sufficient to diagnose or treat asymptomatic relatives.

Urinary glucose tetrasaccharide Glc4 reflects glycogen degradation and supports diagnosis and monitoring, but is not specific and does not replace enzyme testing. CK, AST, ALT and LDH may be elevated; electromyography and biopsy are selective. In late-onset disease, seated and supine forced vital capacity, respiratory pressures, sleep and gas exchange provide more operational information than CK. The functional measurement links the biochemical defect to the clinical decision.

Urgent pathway in the infant

When the phenotype is compatible, enzyme activity, rapid genetics, CRIM status, Glc4, ECG, echocardiography, liver function, CK and respiratory assessment are initiated during the same period. The metabolic center does not wait for a routine outpatient visit. If deficiency is confirmed, therapy starts as soon as possible while characterization is completed. Parallel care reduces a delay during which mass, weakness and immunogenicity may irreversibly alter outcome.

Feeding and swallowing require instrumental assessment when cough, desaturation or poor weight gain suggest aspiration. A nasogastric tube or gastrostomy can reduce risk but does not eliminate reflux and secretions; the decision considers anesthesia and cardiac stability. Safe nutrition supports growth and therapy without imposing the cost of prolonged meals on respiratory muscle.

Respiratory infections accelerate failure and catabolism. Vaccination of the child and contacts, hygiene, early access to cough assistance and a secretion plan reduce hospitalizations. Oxygen alone may mask hypoventilation and increase carbon dioxide; blood gases and ventilation guide the choice. Ventilatory physiology is treated, not just peripheral oxygen saturation.

Anesthesia in the hypertrophied infant is high risk because of obstruction, arrhythmia, weakness and secretions. Before venous access, gastrostomy or biopsy, the necessity of the procedure is verified and a team with pediatric intensive support is used. Preload, heart rate and vascular resistance are maintained while abrupt changes are avoided. Procedural necessity must outweigh a risk that genetic-enzymatic diagnosis often allows clinicians to avoid.

CRIM, antibodies and immune tolerance

CRIM describes the presence of immunologically recognizable endogenous GAA protein. CRIM-negative infants lack protein and recognize recombinant enzyme as highly foreign, with risk of high sustained antibody titers that neutralize uptake and efficacy. Some CRIM-positive patients also develop a significant response. Immunologic stratification should be obtained urgently from genotype and, when necessary, protein analysis.

In high-risk patients, immune tolerance induction is used near the first therapy, with protocols that may include rituximab, methotrexate and immunoglobulins, adapted by the center. Treating established antibodies is more difficult and may require additional strategies. Complete blood count, immunoglobulins, lymphocytes, infections and vaccines enter the plan. Antibody prevention should not delay enzyme therapy but should be coordinated with it.

Antibody titers are measured serially because a low transient response has a different meaning from a high sustained titer. Worsening strength or biomarkers is not automatically attributed to antibodies without examining dose, infections, growth and progression. Neutralizing assays and pharmacokinetics are available at specialized centers. The clinical antibody response arises from the association between laboratory findings and effect, not simple seropositivity.

Immune tolerance exposes patients to B-cell depletion, cytopenias and infections and requires prophylaxis and monitoring. The vaccination schedule is coordinated with the pediatrician and immunologist, knowing that immunoglobulins and rituximab influence response. The family should know which fever and signs require urgent assessment. Immunologic safety is an integral part of the strategy that protects enzyme therapy, not a separate risk delegated after discharge.

Enzyme replacement therapy

Alglucosidase alfa has been shown to improve survival and cardiomyopathy in infantile disease and motor or respiratory function in some late-onset forms. Avalglucosidase alfa is designed to increase mannose-6-phosphate receptor targeting and is available according to age and regulatory indications. Doses and frequency are defined by product labeling, protocols and phenotype; in some infants, high-intensity strategies supported by observational data are used. Individualized dosing remains a specialist act, not a simple weight conversion.

Infusions can cause mild to severe reactions. Premedication, slowing, desensitization and antibody assessment are adapted to the reaction without automatically stopping a life-saving therapy. Venous access, family time and home care influence adherence; repeatedly missed doses change exposure. Infusion quality is part of biological efficacy.

In late-onset disease, cipaglucosidase alfa associated with miglustat is approved in specific settings for adults, while other strategies and gene therapy are under study. Miglustat in this combination stabilizes the enzyme and should not be confused with migalastat used in Fabry disease. Comparisons among products require motor and respiratory endpoints, safety and prior treatment. Pharmacologic precision avoids turning similar names into interchangeable therapies.

Response is measured with ventricular mass index, function, ECG, growth, motor milestones, ventilation and Glc4. In infants, the heart may improve before muscle; rapid echocardiographic regression does not justify reducing therapy. In late-onset disease, walk tests and vital capacity have variability and should be performed using consistent technique. Domain-based response recognizes discordant improvements without selecting only the most favorable one.

Weight gain changes the absolute dose and failure to adjust it produces unintended underdosing. Missed intervals, reduced infusion speed because of reactions and drug loss through the access influence exposure. Periodic audit of weight, dose per kilogram and administrations is simple but clinically important. The dose actually received should be verified before any conclusion about biological refractoriness.

Deterioration during therapy requires differential diagnosis: antibodies, infection, aspiration, scoliosis, growth, dose, new heart disease or neuromuscular progression. Changing product without clarifying the mechanism may not solve the problem. Structured reassessment protects against two opposite simplifications: attributing everything to natural history or promising that a new formulation will correct every domain.

Survivors of infantile disease

Children treated early have created a survivor phenotype with facial weakness, ptosis, dysphagia, speech disorders, hearing loss and variable motor deficits. Some walk and attend school, others depend on ventilation; the heart may be almost normalized in both. Cardioskeletal dissociation requires echocardiographic success not to obscure respiratory, communication and social needs.

Hearing is assessed with age-appropriate methods because unrecognized loss worsens speech and learning. Osteopenia, fractures, contractures and scoliosis result from weakness and immobility and alter ventilation. Rehabilitation, orthopedics and nutrition intervene before advanced deformity. Secondary prevention uses gained survival to preserve participation and autonomy.

Transition to adulthood includes the history of CRIM, immune tolerance, antibody titers, formulation and dose, accesses, ventilation, swallowing, anesthetics and devices. Losing these data forces difficult reconstruction and may expose patients to improper treatment. Documented transition is a planned clinical procedure, not an administrative transfer at a certain age.

Quality of life and caregiver burden are measured and supported. Frequent infusions, ventilation, school and appointments can absorb the entire family organization; home care and coordination reduce sacrifices. Sustainability of care determines long-term adherence and should be considered when comparing apparently equivalent regimens.

Cardiac, respiratory and nutritional support

In an infant with a small cavity and obstruction, diuretics and vasoactive drugs require caution: excessive preload reduction can worsen output, while congestion and respiratory failure must be controlled. Rapid initiation of enzyme therapy is the main causal intervention. Arrhythmias are treated according to mechanism and stability, with anesthesia and procedures managed in an expert setting. Fragile hemodynamics requires integrated pediatric cardiology and intensive care.

Noninvasive or invasive ventilation, cough assistance, vaccinations and early treatment of infections protect respiratory muscle. Swallowing and nutrition should prevent aspiration and catabolism without overfeeding a low-mobility patient. Physiotherapy maintains function while avoiding overexertion. Respiratory care determines survival as much as regression of hypertrophy.

Infantile survivors may develop residual weakness, ptosis, hearing loss, osteopenia and motor or feeding difficulties. Improvement of the heart should not end follow-up. In late-onset forms, pregnancy, surgery and infections require assessment of supine ventilation and cough because normal awake saturation does not exclude nocturnal hypoventilation. The new chronicity requires seamless pediatric and adult expertise.

Late-onset disease, activity and pregnancy

In adults, supine forced vital capacity may fall more than seated capacity and signal diaphragmatic weakness. Polysomnography or capnography detects nocturnal hypoventilation before overt sleepiness. Noninvasive support is titrated to ventilation and symptoms, not to a single saturation. Diaphragmatic reserve is an essential therapeutic endpoint and a determinant of anesthetic safety.

Moderate individualized aerobic and strength exercise, accompanied by adequate nutrition, may improve efficiency without causing overexertion. Pain, dark urine, falls or prolonged recovery require review. Extreme high-protein or restrictive regimens do not replace enzyme therapy and may be inappropriate. Dosed rehabilitation uses functional goals and recovery periods rather than generic prescriptions.

Pregnancy increases respiratory work and lordosis and may reveal weakness. Preconception counseling assesses supine function, cough, mobility, anesthesia and postpartum support; use of specific therapy is discussed based on available data and maternal risk. Fetal genetic risk depends on the partner's status. Obstetric planning separates recessive transmission from the mother's cardiorespiratory capacity.

A person with two GAA variants transmits one variant to all children; disease in the children requires the other parent to be a carrier and transmit their allele. Partner testing and counseling can quantify risk without assuming consanguinity. Reproductive genetics uses classified familial variants rather than a generic calculation based on disease rarity.

Screening, family and prognosis

Newborn screening reduces delay in infantile disease, but its effectiveness depends on rapid confirmation and access to therapy. Pseudodeficiency and late-onset variants create families with a clinically healthy child at future risk; both overly intensive monitoring and reassurance without a protocol are harmful. Surveillance of late-onset genotypes uses motor signs, CK and respiratory function to identify onset.

Recessive inheritance gives siblings of a proband, when both parents are carriers, a 25% risk of disease, a 50% chance of being carriers and a 25% chance of inheriting neither familial variant in each pregnancy. Relatives are studied with targeted testing and, when necessary, enzyme activity. Reproductive counseling and prenatal or preimplantation diagnosis depend on the family's informed choices. Family cascade testing is particularly urgent in newborn siblings.

Infantile prognosis has improved enormously but remains heterogeneous. Therapy in the first days or weeks, antibody prevention and multidisciplinary support offer the best outcomes; diagnosis after advanced failure reduces reversibility. In late-onset disease, therapy tends to stabilize or modestly improve some domains, while respiratory progression requires permanent surveillance. Contemporary prognosis should be discussed by subtype and response, not using mortality from the pre-enzyme era.

A patient with apparently stable late-onset disease may slowly lose function, and the decision to start or change therapy requires reliable serial measurements. Vital capacity, walk testing, strength and daily activity are interpreted together, accounting for learning and motivation. The functional slope is often more informative than position relative to a threshold and helps distinguish true stability from test variability.

Scoliosis and chest-wall rigidity can limit ventilation independently of strength and make spirometry more complex. Early orthopedic assessment, seating and aids improve posture and cough; surgery requires a center with respiratory expertise. Chest mechanics enters the Pompe plan as a modifiable determinant of function, not an aesthetic consequence of weakness.

Falls, fractures and pain reduce mobility and trigger further deconditioning. Bone density, vitamin D, nutrition and home safety are assessed according to risk. A physiotherapy program should avoid prolonged immobilization after an event. Fall prevention indirectly protects ventilation and metabolism by interrupting a cycle that no infusion can correct alone.

Home infusion care is appropriate only after stability and a plan for reactions. In infants, immunomodulated patients or after severe events, the hospital center retains advantages. Access to emergency medication and trained staff is essential. The infusion setting is chosen according to clinical risk and quality, not exclusively convenience or cost.

Gene therapy, hepatic secretion of enzyme and strategies to improve autophagy are under study. Vectors, pre-existing immunity, dose, liver and durability remain challenges; experimental participation does not mean stopping effective enzyme therapy outside a protocol. Pompe research should measure heart, muscle and respiration long term, not merely a transient increase in enzyme activity.

In adult relatives with late-onset variants, the start of monitoring and therapy is based on objective signs and genotype history, not only on the proband's age. Some remain presymptomatic for years, while others already show diaphragmatic weakness. Family surveillance should be sensitive enough to detect onset without turning every biallelic carrier into a symptomatic patient before evidence appears.

The emergency plan lists diagnosis, ventilation, access, therapy and contacts, as well as instructions for infection and fasting. In the emergency department, a radiograph does not always distinguish pneumonia, atelectasis and weakness; blood gases and cough assessment add information. The coordinated response reduces the risk that oxygen and antibiotics are given without treating hypoventilation.

Bulbar function is reassessed because swallowing that is safe at one age may deteriorate or fail to keep pace with different consistencies. Weak voice, long meals and recurrent infections are early signs. Swallowing surveillance prevents silent aspiration and links speech therapy, nutrition and pulmonology before severe pneumonia.

Sleep is a natural laboratory of respiratory reserve: morning headache, nightmares, sleepiness and awakenings may precede daytime dyspnea. Oximetry alone may not detect hypercapnia, especially with oxygen. Nocturnal capnography and an appropriate study define support and allow assessment of adherence and effectiveness.

During infections, weak cough may require mechanical assistance and suction in addition to antibiotics. Sedatives and antitussives are used cautiously because they reduce ventilation and clearance. Secretion management is often the intervention that prevents intubation and should be taught to the family before the first crisis.

Annual reassessment of the equipment set checks the ventilator, interface, insufflator-exsufflator and batteries. Home reliability is a clinical requirement: a prescribed device that is not tolerated, maintained or backed up does not provide the expected protection.